Americans' Rx Drug Spending Shows Rare Drop in 2012
Spending on prescription medicines in the U.S. fell for the first time in decades last year, as cash-strapped consumers continued to cut back on use of health-care services.
generic drugs
Bristol-Myers Earnings Plunge as Sales of Plavix Plummet
Bristol-Myers Squibb posted a 45 percent drop in first-quarter profit as revenue from its Plavix blood-thinning drug plunged 95%.
Supreme Court to Hear Case Alleging 'Flawed' Generic Drug
The Supreme Court will hear arguments Tuesday in a case that could decide whether generic drugmakers can be held liable for alleged flaws in the designs of their medications.
11 Easy and Great Ways to Save Money in 2013
With the prospect of higher taxes and federal budget cuts looming on Dec. 31, here are 11 easy ways you can save money and/or put a few extra dollars back in your pocket in 2013.
Painless Tips on Shopping for Headache Medicine -- Savings Experiment
Experts compare name brand and generic headache medicine for value, effectiveness and savings.
What Not to Do When Filling a Prescription
Cold and flu season is upon us. Americans spend $400 million on prescription drugs to relieve the symptoms, according to one study, and some of them spend too much. DailyFinance's Laura Rowley looks at what not to do when filling a prescription.
The Financial Landscape: Big Pharma Wins; So Does Greece
It's a good day to be a drugmaker after two pro-business Supreme Court rulings favored the industry. And it's an even better day for those who are counting on the EU bailing out Greece. But the folks at Google may want to search for "defense lawyers" -- they may be seeing subpoenas shortly.
Pfizer Sells Capsugel: Will More Asset Sales Follow?
On Monday, Pfizer announced it would sell its Capsugel business to private-equity firm KKR for $2.375 billion. If the hints the drugmaker has been giving lately are true, the move could be the start of two years of major asset sales. Here's what's ahead for the world's biggest pharmaceutical company.
The Five Best-Performing Biotech Stocks of 2011 -- So Far
Pharmaceuticals are facing big patent cliff problems this year, but several biotechnology stocks have been doing quite well: Their biologic drugs command high prices, tend become blockbusters, and they are in far less danger from generic competition. Here are the big winners so far this year.
Inside Wall Street: How Goldman Is Playing the Coming Tide of Generic Drugs
Generic drugs are expected to enjoy a banner year in 2011, prompting some investment pros to reformulate their portfolios to get a jump on the transition. For Goldman Sachs, that means betting on several wholesale distributors and retail drugstores that stand to benefit.
Top-Selling Drugs About to Lose Patent Protection
The pharmaceutical industry is ready to fall off a cliff -- a "patent cliff." Over the next few years, some of the world's most popular and lucrative medicines will go off patent, and generic competition will siphon an estimated quarter of a trillion dollars from drugmakers' bottom lines.
Still No Deal Between Sanofi-Aventis and Genzyme
What is preventing the French pharmaceutical group and U.S. biotech from reaching a merger agreement?